Partnering Opportunities

Bio-Path seeks to apply DNAbilize®, our proprietary neutral-lipid delivery technology, to new protein targets in cancer and other disease indications.

We are interested in pursuing a wide-ranging, proactive licensing program to include co-development of specific liposomal antisense drug candidates; sub-license the delivery template for outside development of liposomal antisense drug candidates; or out-license a partially developed drug for final development and marketing.